Basit öğe kaydını göster

dc.contributor.authorAk, Naziye
dc.contributor.authorOzluk, Yasemin
dc.contributor.authorEkiz, Feza
dc.contributor.authorTural, Deniz
dc.contributor.authorEkenel, Meltem
dc.contributor.authorOzcan, Faruk
dc.contributor.authorBasaran, Mert
dc.contributor.authorYirgin, İnci
dc.contributor.authorPaksoy, Nail
dc.contributor.authorErdem, Selcuk
dc.contributor.authorKaraca, Mert
dc.contributor.authorPehlivan, Metin
dc.date.accessioned2021-12-10T12:31:58Z
dc.date.available2021-12-10T12:31:58Z
dc.date.issued2021
dc.identifier.citationPaksoy N., Erdem S., Karaca M., Ak N., Pehlivan M., Yirgin İ., Ozluk Y., Ekiz F., Tural D., Ekenel M., et al., "Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report.", Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, sa.0, 2021
dc.identifier.issn1078-1552
dc.identifier.othervv_1032021
dc.identifier.otherav_c324905d-a71d-4a66-811a-142cc0360b64
dc.identifier.urihttp://hdl.handle.net/20.500.12627/174082
dc.identifier.urihttps://doi.org/10.1177/10781552211020802
dc.description.abstractBackground Transcription factor E3 (TFE3) related renal cell carcinomas constitute a very small percent of all renal tumors in adults. Prognosis mainly depends on the stage of the disease at the time of diagnosis which is often poor. There is yet to be a standardized treatment protocol. Treatment options include agents identical to TFE3(-) cell renal carcinoma treatment. We present a case of a young woman with a rapidly progressing metastatic TFE3 (+) renal cell carcinoma. Case report A 31 year old female presented with abdominal mass, distension, nausea. Initial tests and tumor markers found to be normal. Abdominal CT scan revealed a left retroperitoneal mass along with three other neighboring masses in liver manifesting as metastases. Trucut biopsy and immunohistochemical staining confirmed the retroperitoneal mass as TFE3 (+) renal cell carcinoma. Management and outcome: Sunitinib, pazopanib, nivolumab, axitinib treatments are consecutively given after surgery. It is noteworthy that rapid progression was observed under nivolumab treatment. Discussion During surveillance, rapid progression is noted under consecutive immunotherapy which was unexpected. Thus, there is a need for more standardized treatment protocols and invention of new agents for management of TFE3 (+) renal cell carcinoma.
dc.language.isoeng
dc.subjectSurgery
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectÜROLOJİ VE NEFROLOJİ
dc.subjectCERRAHİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectCerrahi Tıp Bilimleri
dc.subjectÜroloji
dc.subjectNephrology
dc.subjectUrology
dc.subjectHealth Sciences
dc.titleMultidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report.
dc.typeMakale
dc.relation.journalJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
dc.contributor.departmentİstanbul Üniversitesi , Onkoloji Enstitüsü , Klinik Onkoloji Ana Bilim Dalı
dc.identifier.issue0
dc.contributor.firstauthorID2737086


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster